Abstract by The Health Policy Partnership entitled "System-Level Barriers to
Uptake of Existing and Novel Radioimmunotherapy for People with Lymphoma" will
be presented at the 63[rd] ASH Annual Meeting, 11-14 December 2021

Oslo, Norway, 9 November 2021

Nordic Nanovector ASA (OSE: NANOV) a clinical-stage biotechnology company
dedicated to extending and improving the lives of patients with haematological
cancers, is supporting an independent government affairs project led by The
Health Policy Partnership (HPP), a specialist health policy research
organisation. Within this project, an international framework (the Radioligand
Therapy Readiness Assessment Framework) has been assembled to assess health
system readiness for the use of radioligand therapy and to identify policy
changes that could facilitate appropriate integration of this innovative cancer
treatment modality. The framework can be adapted to any country or health
service context, and HPP has worked with experts to apply the framework
initially to the US and UK health systems.

The project was developed by HPP working with an international expert panel of
nuclear medicine and oncology/haematology experts as well as representatives
from patient advocacy organizations. This is a multi-funded project. Full
details of the project can be found www.radioligandtherapy.com

Radioligand therapy, a term which is used to refer to peptide receptor
radionuclide therapy (PRRT), prostate-specific membrane antigen (PSMA) therapy,
and radioimmunotherapy, is a novel, highly targeted therapeutic modality that
combines a cancer targeting ligand and a radioisotope, emitting radiation to
damage cancer cell DNA and prevent replication. Because radioligand therapy is
highly targeted to cancer cells, healthy cells are left largely unaffected,
reducing treatment side effects and improving their tolerability[1]. However,
patient access to radioligand therapy is highly variable today. Changes within
healthcare system infrastructures are needed to improve the availability of
these innovative therapies.

The framework enables detailed analysis of a health system and helps to identify
areas that clinicians, researchers, patient advocates and policymakers could
change to improve readiness for radioligand therapies and enable their
appropriate integration into routine cancer care. The framework has been applied
to the US and UK health systems with guidance from national expert advisory
groups. The adapted framework for the UK was launched in September 2021 and work
from the US was published in early November 2021.

Marco Renoldi, Nordic Nanovector's Chief Operating Officer, said: "Nordic
Nanovector is proud to support this important initiative, which is part of
ongoing efforts to positively change the healthcare landscape and improve
appropriate clinical adoption of radioligand therapies. This modality has
demonstrated promising clinical efficacy and tolerability in a wide range of
cancer types, including neuroendocrine neoplasms, lymphoma and prostate cancer,
where there is still a significant unmet need. Our own candidate is among a
growing pipeline of novel radioligand therapies that are progressing through
clinical development. It is important that eligible patients have access to
these targeted and well-tolerated therapies given their potential benefits and
once they are approved, this framework will be crucial to helping prepare
healthcare systems for their appropriate use."

An abstract by The Health Policy Partnership entitled "System-Level Barriers to
Uptake of Existing and Novel Radioimmunotherapy for People with Lymphoma" will
be presented at the 63[rd] ASH Annual Meeting, 11-14 December 2021. The abstract
is available online at
https://ash.confex.com/ash/2021/webprogram/Paper144904.html

 1. Herrmann K, Schwaiger M, Lewis JS, et al. 2020. The Lancet Oncology 21(3):
e146-e56

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 203 926 8535
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found
at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7Cb7a23ba8eace4c1e863308d97799ed1f%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637672326009184815%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=NOyVW%2B%2F3LdP8et7SyKO6Bze%2FFG2Z
%
2F4IBg8BfYb%2B87dU%3D&reserved=0).

About The Health Policy Partnership:

The Health Policy Partnership (https://www.healthpolicypartnership.com/) is an
independent health policy research organisation, working with partners across
the health spectrum to drive the policy and system changes that will help
improve people's health.

About the project:

The radioligand therapy readiness assessment
project (https://www.radioligandtherapy.com/) is led by The Health Policy
Partnership with guidance from a multi-stakeholder International Advisory Group.
The group has full editorial control over all international-level outputs, with
national-level groups maintaining editorial control for national outputs. This
is a multi-funded project.

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.